Rebecca Kahn1,2, Inga Holmdahl1, Sujan Reddy2, John Jernigan2, Michael J Mina1,3,4, Rachel B Slayton2. 1. Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 2. COVID-19 Response, US Centers for Disease Control and Prevention, Atlanta, Georgia. 3. Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 4. Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND: Nursing home residents and staff were included in the first phase of COVID-19 vaccination in the United States. Because the primary trial endpoint was vaccine efficacy (VE) against symptomatic disease, there are limited data on the extent to which vaccines protect against SARS-CoV-2 infection and the ability to infect others (infectiousness). Assumptions about VE against infection and infectiousness have implications for possible changes to infection prevention guidance for vaccinated populations, including testing strategies. METHODS: We use a stochastic agent-based SEIR model of a nursing home to simulate SARS-CoV-2 transmission. We model three scenarios, varying VE against infection, infectiousness, and symptoms, to understand the expected impact of vaccination in nursing homes, increasing staff vaccination coverage, and different screening testing strategies under each scenario. RESULTS: Increasing vaccination coverage in staff decreases total symptomatic cases in each scenario. When there is low VE against infection and infectiousness, increasing staff coverage reduces symptomatic cases among residents. If vaccination only protects against symptoms, but asymptomatic cases remain infectious, increased staff coverage increases symptomatic cases among residents through exposure to asymptomatic but infected staff. High frequency testing is needed to reduce total symptomatic cases if the vaccine has low efficacy against infection and infectiousness, or only protects against symptoms. CONCLUSIONS: Encouraging staff vaccination is not only important for protecting staff, but might also reduce symptomatic cases in residents if a vaccine confers at least some protection against infection or infectiousness. SUMMARY: The extent of efficacy of SARS-CoV-2 vaccines against infection, infectiousness, or disease, impacts strategies for vaccination and testing in nursing homes. If vaccines confer some protection against infection or infectiousness, encouraging vaccination in staff may reduce symptomatic cases in residents.
BACKGROUND: Nursing home residents and staff were included in the first phase of COVID-19 vaccination in the United States. Because the primary trial endpoint was vaccine efficacy (VE) against symptomatic disease, there are limited data on the extent to which vaccines protect against SARS-CoV-2 infection and the ability to infect others (infectiousness). Assumptions about VE against infection and infectiousness have implications for possible changes to infection prevention guidance for vaccinated populations, including testing strategies. METHODS: We use a stochastic agent-based SEIR model of a nursing home to simulate SARS-CoV-2 transmission. We model three scenarios, varying VE against infection, infectiousness, and symptoms, to understand the expected impact of vaccination in nursing homes, increasing staff vaccination coverage, and different screening testing strategies under each scenario. RESULTS: Increasing vaccination coverage in staff decreases total symptomatic cases in each scenario. When there is low VE against infection and infectiousness, increasing staff coverage reduces symptomatic cases among residents. If vaccination only protects against symptoms, but asymptomatic cases remain infectious, increased staff coverage increases symptomatic cases among residents through exposure to asymptomatic but infected staff. High frequency testing is needed to reduce total symptomatic cases if the vaccine has low efficacy against infection and infectiousness, or only protects against symptoms. CONCLUSIONS: Encouraging staff vaccination is not only important for protecting staff, but might also reduce symptomatic cases in residents if a vaccine confers at least some protection against infection or infectiousness. SUMMARY: The extent of efficacy of SARS-CoV-2 vaccines against infection, infectiousness, or disease, impacts strategies for vaccination and testing in nursing homes. If vaccines confer some protection against infection or infectiousness, encouraging vaccination in staff may reduce symptomatic cases in residents.
Authors: Roman Wölfel; Victor M Corman; Wolfgang Guggemos; Michael Seilmaier; Sabine Zange; Marcel A Müller; Daniela Niemeyer; Terry C Jones; Patrick Vollmar; Camilla Rothe; Michael Hoelscher; Tobias Bleicker; Sebastian Brünink; Julia Schneider; Rosina Ehmann; Katrin Zwirglmaier; Christian Drosten; Clemens Wendtner Journal: Nature Date: 2020-04-01 Impact factor: 49.962
Authors: Qun Li; Xuhua Guan; Peng Wu; Xiaoye Wang; Lei Zhou; Yeqing Tong; Ruiqi Ren; Kathy S M Leung; Eric H Y Lau; Jessica Y Wong; Xuesen Xing; Nijuan Xiang; Yang Wu; Chao Li; Qi Chen; Dan Li; Tian Liu; Jing Zhao; Man Liu; Wenxiao Tu; Chuding Chen; Lianmei Jin; Rui Yang; Qi Wang; Suhua Zhou; Rui Wang; Hui Liu; Yinbo Luo; Yuan Liu; Ge Shao; Huan Li; Zhongfa Tao; Yang Yang; Zhiqiang Deng; Boxi Liu; Zhitao Ma; Yanping Zhang; Guoqing Shi; Tommy T Y Lam; Joseph T Wu; George F Gao; Benjamin J Cowling; Bo Yang; Gabriel M Leung; Zijian Feng Journal: N Engl J Med Date: 2020-01-29 Impact factor: 176.079
Authors: Kristina L Bajema; Ryan E Wiegand; Kendra Cuffe; Sadhna V Patel; Ronaldo Iachan; Travis Lim; Adam Lee; Davia Moyse; Fiona P Havers; Lee Harding; Alicia M Fry; Aron J Hall; Kelly Martin; Marjorie Biel; Yangyang Deng; William A Meyer; Mohit Mathur; Tonja Kyle; Adi V Gundlapalli; Natalie J Thornburg; Lyle R Petersen; Chris Edens Journal: JAMA Intern Med Date: 2021-04-01 Impact factor: 21.873
Authors: Daniel Butler; Christopher Mozsary; Cem Meydan; Jonathan Foox; Joel Rosiene; Alon Shaiber; David Danko; Ebrahim Afshinnekoo; Matthew MacKay; Fritz J Sedlazeck; Nikolay A Ivanov; Maria Sierra; Diana Pohle; Michael Zietz; Undina Gisladottir; Vijendra Ramlall; Evan T Sholle; Edward J Schenck; Craig D Westover; Ciaran Hassan; Krista Ryon; Benjamin Young; Chandrima Bhattacharya; Dianna L Ng; Andrea C Granados; Yale A Santos; Venice Servellita; Scot Federman; Phyllis Ruggiero; Arkarachai Fungtammasan; Chen-Shan Chin; Nathaniel M Pearson; Bradley W Langhorst; Nathan A Tanner; Youngmi Kim; Jason W Reeves; Tyler D Hether; Sarah E Warren; Michael Bailey; Justyna Gawrys; Dmitry Meleshko; Dong Xu; Mara Couto-Rodriguez; Dorottya Nagy-Szakal; Joseph Barrows; Heather Wells; Niamh B O'Hara; Jeffrey A Rosenfeld; Ying Chen; Peter A D Steel; Amos J Shemesh; Jenny Xiang; Jean Thierry-Mieg; Danielle Thierry-Mieg; Angelika Iftner; Daniela Bezdan; Elizabeth Sanchez; Thomas R Campion; John Sipley; Lin Cong; Arryn Craney; Priya Velu; Ari M Melnick; Sagi Shapira; Iman Hajirasouliha; Alain Borczuk; Thomas Iftner; Mirella Salvatore; Massimo Loda; Lars F Westblade; Melissa Cushing; Shixiu Wu; Shawn Levy; Charles Chiu; Robert E Schwartz; Nicholas Tatonetti; Hanna Rennert; Marcin Imielinski; Christopher E Mason Journal: Nat Commun Date: 2021-03-12 Impact factor: 14.919
Authors: Lindsey R Baden; Hana M El Sahly; Brandon Essink; Karen Kotloff; Sharon Frey; Rick Novak; David Diemert; Stephen A Spector; Nadine Rouphael; C Buddy Creech; John McGettigan; Shishir Khetan; Nathan Segall; Joel Solis; Adam Brosz; Carlos Fierro; Howard Schwartz; Kathleen Neuzil; Larry Corey; Peter Gilbert; Holly Janes; Dean Follmann; Mary Marovich; John Mascola; Laura Polakowski; Julie Ledgerwood; Barney S Graham; Hamilton Bennett; Rolando Pajon; Conor Knightly; Brett Leav; Weiping Deng; Honghong Zhou; Shu Han; Melanie Ivarsson; Jacqueline Miller; Tal Zaks Journal: N Engl J Med Date: 2020-12-30 Impact factor: 91.245
Authors: Chantal B F Vogels; Anderson F Brito; Anne L Wyllie; Joseph R Fauver; Isabel M Ott; Chaney C Kalinich; Mary E Petrone; Arnau Casanovas-Massana; M Catherine Muenker; Adam J Moore; Jonathan Klein; Peiwen Lu; Alice Lu-Culligan; Xiaodong Jiang; Daniel J Kim; Eriko Kudo; Tianyang Mao; Miyu Moriyama; Ji Eun Oh; Annsea Park; Julio Silva; Eric Song; Takehiro Takahashi; Manabu Taura; Maria Tokuyama; Arvind Venkataraman; Orr-El Weizman; Patrick Wong; Yexin Yang; Nagarjuna R Cheemarla; Elizabeth B White; Sarah Lapidus; Rebecca Earnest; Bertie Geng; Pavithra Vijayakumar; Camila Odio; John Fournier; Santos Bermejo; Shelli Farhadian; Charles S Dela Cruz; Akiko Iwasaki; Albert I Ko; Marie L Landry; Ellen F Foxman; Nathan D Grubaugh Journal: Nat Microbiol Date: 2020-07-10 Impact factor: 30.964
Authors: Joseph Walker; Prabasaj Paul; Kathleen Dooling; Sara Oliver; Pragati Prasad; Molly Steele; Paul A Gastañaduy; Michael A Johansson; Matthew Biggerstaff; Rachel B Slayton Journal: Vaccine Date: 2022-02-07 Impact factor: 4.169